Sera Prognostics (SERA)
(Delayed Data from NSDQ)
$7.21 USD
+0.29 (4.19%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $7.21 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.21 USD
+0.29 (4.19%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $7.21 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth A Momentum D VGM
Zacks News
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sera Prognostics (SERA) delivered earnings and revenue surprises of -8.70% and 70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Pediatrix Medical Group (MD) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Pediatrix Medical Group (MD) delivered earnings and revenue surprises of 9.68% and 0.24%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Cencora (COR) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Cencora (COR) delivered earnings and revenue surprises of 5.03% and 0.90%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Avantor, Inc. (AVTR) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Avantor (AVTR) delivered earnings and revenue surprises of 8.70% and 0.01%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Encompass Health (EHC), Piedmont Expand Ties to Serve Georgia
by Zacks Equity Research
Encompass Health (EHC) expands its partnership with Piedmont to better serve Georgians with the Walton Rehabilitation Hospital.
Teladoc (TDOC) Harnesses AI for Diabetes Care, Stock Rises 6.7%
by Zacks Equity Research
AI can help Teladoc (TDOC) to streamline healthcare delivery, making it more efficient and scalable.
Elevance Health (ELV) Rallies 11.8% YTD: More Room to Run?
by Zacks Equity Research
Elevance Health's (ELV) performance benefits from new contract wins, a strong Carelon segment and recovering Medicaid business.
Brookdale (BKD) Sees 31 Months of Y/Y Occupancy Growth Streak
by Zacks Equity Research
Brookdale's (BKD) weighted average occupancy for the second quarter-to-date rises 160 bps year over year to 78%.
Select Medical (SEM) Rises 42.4% YTD: More Growth Ahead?
by Zacks Equity Research
Select Medical (SEM) will continue to gain from rising admissions within the Critical Illness Recovery Hospital and Rehabilitation Hospital segments.
Will UnitedHealth (UNH) Dividend Hike Fail to Excite Investors?
by Zacks Equity Research
UnitedHealth's (UNH) strong financial position supports its shareholder value boosting efforts.
Cigna's (CI) Express Scripts Collaborates With CPESN USA
by Zacks Equity Research
Cigna's (CI) Express Scripts collaborates with CPESN USA in a bid to enhance care delivery for hypertension and diabetes patients.
Encompass Health (EHC) JV Opens Atlanta Rehabilitation Hospital
by Zacks Equity Research
The new facility in Georgia marks the 162nd inpatient rehabilitation hospital of Encompass Health (EHC) in the country.
Encompass Health (EHC) Opens Rehabilitation Hospital in Ballwin
by Zacks Equity Research
The 40-bed inpatient rehabilitation hospital is a JV between Encompass Health (EHC) and BJC HealthCare.
Elevance (ELV) Rises 14.9% YTD: What Lies Ahead for Investors?
by Zacks Equity Research
Elevance (ELV) continues to focus on increasing shareholder value with consistent dividend payouts and stock repurchases.
Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Sera Prognostics (SERA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sera Prognostics (SERA) delivered earnings and revenue surprises of 0% and 56.84%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Sera Prognostics, Inc. (SERA) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Sera Prognostics, Inc. (SERA) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why You Should Bet on These 5 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Yum Brands (YUM), Inter Parfums (IPAR), TripAdvisor (TRIP) and Sera Prognostics (SERA).
Why You Should Bet on 4 Top-Ranked Stocks With Rising P/E
by Sanghamitra Saha
Tap four stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Scholar Rock (SRRK), PTK Acquisition (VLN), OI Glass (OI) and Sera Prognostics (SERA).
Sera Prognostics, Inc. (SERA) Loses -32.38% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Sera Prognostics, Inc. (SERA) Loses -38.49% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Sera Prognostics, Inc. (SERA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 0% and 29.47%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) Reports Q1 Loss
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 2.86% and 0%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Alignment Healthcare (ALHC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alignment Healthcare (ALHC) delivered earnings and revenue surprises of 20% and 1.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Eli Lilly (LLY) Q1 Earnings Lag Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of -6.36% and 2.17%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?